GUD vs. TLRY, CRON, THCX, DHT.UN, WEED, CPH, ACB, SUGR, OGI, and FIRE
Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Tilray Brands (TLRY), Cronos Group (CRON), Hydropothecary (THCX), DRI Healthcare Trust (DHT.UN), Canopy Growth (WEED), Cipher Pharmaceuticals (CPH), Aurora Cannabis (ACB), SugarBud Craft Growers (SUGR), Organigram (OGI), and Supreme Cannabis (FIRE). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Knight Therapeutics vs. Its Competitors
Knight Therapeutics (TSE:GUD) and Tilray Brands (TSE:TLRY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.
Knight Therapeutics has a net margin of -8.81% compared to Tilray Brands' net margin of -30.02%. Knight Therapeutics' return on equity of -4.04% beat Tilray Brands' return on equity.
Knight Therapeutics presently has a consensus target price of C$7.15, suggesting a potential upside of 14.77%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Knight Therapeutics is more favorable than Tilray Brands.
Knight Therapeutics has a beta of 0.219245, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 3.71147, suggesting that its share price is 271% more volatile than the S&P 500.
In the previous week, Tilray Brands had 3 more articles in the media than Knight Therapeutics. MarketBeat recorded 3 mentions for Tilray Brands and 0 mentions for Knight Therapeutics. Tilray Brands' average media sentiment score of 0.36 beat Knight Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media.
16.3% of Knight Therapeutics shares are held by institutional investors. Comparatively, 4.7% of Tilray Brands shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Comparatively, 0.7% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Knight Therapeutics has higher earnings, but lower revenue than Tilray Brands.
Summary
Knight Therapeutics beats Tilray Brands on 10 of the 16 factors compared between the two stocks.
Get Knight Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Knight Therapeutics Competitors List
Related Companies and Tools
This page (TSE:GUD) was last updated on 9/18/2025 by MarketBeat.com Staff
Free GUD Stock Alerts